Hyperfine (HYPR) Cash & Equivalents Growth (1y) (2021 - 2026)
Hyperfine (HYPR) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -22.13% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 23.57% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -7.71% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | -10.02% |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 141.82% |
| 10 | Hyperfine | 94.51 Mn | 53.23 Mn | 1.98 Mn | 23.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.22% |
| Dec 31, 2025 | -6.80% |
| Sep 30, 2025 | -52.88% |
| Jun 30, 2025 | -52.76% |
| Mar 31, 2025 | -47.64% |
| Dec 31, 2024 | -49.93% |
| Sep 30, 2024 | -46.43% |
| Jun 30, 2024 | -42.72% |
| Mar 31, 2024 | -39.24% |
| Dec 31, 2023 | -36.00% |
| Sep 30, 2023 | -35.52% |
| Jun 30, 2023 | -35.25% |
| Mar 31, 2023 | -35.62% |
| Dec 31, 2022 | -37.68% |
| Sep 30, 2022 | 102.34% |
| Jun 30, 2022 | 87.49% |
| Mar 31, 2022 | 87.38% |
| Dec 31, 2021 | 200.75% |